Navigation Links
Second-line CML drugs evoke faster response than front-line therapy
Date:12/7/2009

NEW ORLEANS ― Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

Initial therapy for CML remains imatinib, a Novartis drug known as Gleevec, which has increased the five-year survival rate for the disease from 50 percent to 90 percent of patients. In separate clinical trials, M. D. Anderson researchers are comparing nilotinib, a Novartis drug known as Tasigna, and dasatinib, a Bristol-Myers Squibb drug known as Sprycel, to historical results from earlier trials of imatinib.

"More patients taking nilotinib or dasatinib are achieving complete responses more quickly than they do on either of two daily doses of imatinib," said Jorge Cortes, M.D., professor in M. D. Anderson's Leukemia Department and leader of both studies.

For example, 96 percent of those taking nilotinib and 94 percent of those on dasatinib reached a complete cytogenetic response at six months, compared with 54 percent of those taking 400 mg a day of imatinib and 85 percent of those taking 800 mg. Over the longer term up to 30 months, complete cytogenetic response induced by the two drugs is comparable to that of the higher-dose imatinib.

Complete cytogenetic response is the absence of the defective chromosome that causes the disease.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. All three drugs are tyrosine kinase inhibitors, which block the action of Bcr-Abl. Nilotinib and dasatinib target more variations of the protein and often work after imatinib has failed. Both are approved by the U.S. Food and Drug
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. AHF/India Cares Provides Second-line AIDS Drugs to Activists in India
2. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
3. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
4. More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro
5. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
6. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
7. New review suggests caution on drugs to raise good cholesterol
8. Can cancer drugs combine forces?
9. Study provides hope that some transplant patients could live free of antirejection drugs
10. Study provides hope that some transplant patients could live free of anti-rejection drugs
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives ... Application & Geography – Trends & Forecast to 2018," ... forecasting of market volume and value. The report also ... The market of phthalic anhydride is projected to grow ... million by 2018, with a CAGR of 5.24% from ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... 2014 The fastest-growing mobile technology is ... measurement of LTE networks continues to grow due to ... devices have increased mobile data traffic, which is a ... market. Communications Test and Measurement equipment comply with industry ... Communications Test and Measurement Market is estimated to grown ...
(Date:7/12/2014)... News) -- If you make exercise fun, you,ll eat less ... 56 adults were led on a 1.4-mile walk and were ... scenic walk. The participants were given lunch after the walk, ... ate 35 percent more chocolate pudding for dessert than those ... another experiment, 46 adults were given mid-afternoon snacks after their ...
(Date:7/12/2014)... ON Canada (PRWEB) July 12, 2014 Sean Francis, ... for throwing out special challenges to his clients. He’s also known ... Club. He recently found a way to combine the two and ... has raised $2,000 for the Boys and Girls Club. , The ... Program, which started on June 23rd. Francis sent out emails and ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... ... ... ... ...
... ... , ... , , , ... NEW YORK , March 4 ...
... ... ... ... ...
... third leading cause of cancer death among men and ... CRC screening receive it. The American Gastroenterological Association (AGA) ... of screening and to encourage everyone age 50 and ... that those without insurance have limited access to screening, ...
... Calculus Bovis compound preparation (ICCBco) in the treatment ... schistosomiasis as the experimental animal model, a research ... trial to observe pathological changes and pathological effect ... the lung tissue of portal hypertensive rabbits with ...
... at risk, but elderly women are too, study finds , ... common cause of shoulder dislocation, and young males have the ... study shows. , Researchers studied 8,940 shoulder dislocations treated at ... to 2006 and found that the overall incidence rate was ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Cowen Group Announces Promotions in Health Care Investment Banking 2Health News:Cowen Group Announces Promotions in Health Care Investment Banking 3Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 2Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 3Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 4Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 5Health News:Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus 6Health News:Physicians come together on National Colorectal Cancer Awareness and Screening Day 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Shoulder Dislocations a Sports Hazard 2
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... YORK, July 13, 2011 Reportlinker.com announces ... available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0572968/Pharmaceutical-Wholesale-and-Distribution-Industry-World-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Wholesali ... decade affect those activities? ...
... NATICK, Mass., July 12, 2011 RegenoCELL Therapeutics, Inc. ... F. Mongiardo, Chief Executive Officer, reported that plans are ... the United States and Europe for its stem cell ... Regenocell, Ltd., reported that it expects to begin marketing ...
Cached Medicine Technology:Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 2Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 3Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 4Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 5Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 6Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 7Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 8Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 9Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 10Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 11Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 12Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 13RegenoCELL Gives Second Half Update 2RegenoCELL Gives Second Half Update 3RegenoCELL Gives Second Half Update 4RegenoCELL Gives Second Half Update 5RegenoCELL Gives Second Half Update 6
... breakthrough in specimen radiography. The XPERT represents a ... shades of gray in every digital x-ray image, ... in density that heretofore were lost to the ... 2 x 2 to 8 x 8 in ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... The 6303 is an affordable ... provide full height, seat, and back ... 6303 accepts the full line of ... the perfect table for your needs; ...
... Sonesta 6202 is the ultimate ... our most popular accessories, the ... a myriad of exam and ... quiet) motors allow fast & ...
Medicine Products: